home / stock / celuw / celuw news

CELUW News and Press, Celularity Inc. Warrant From 03/20/24

Stock Information
Company Name: Celularity Inc. Warrant
Stock Symbol: CELUW
Market: NASDAQ
Website: celularity.com
Menu
CELUW CELUW Quote CELUW Short CELUW News CELUW Articles CELUW Message Board
Get CELUW Alerts

News, Short Squeeze, Breakout and More Instantly...
CELUW - Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a reques...
CELUW - Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company...

CELUW - Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity” or the “Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company...

CELUW - Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present in vivo data from its T-cell t...
CELUW - Celularity Announces 1-for-10 Reverse Stock Split

FLORHAM PARK, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Celularity, Inc. (Nasdaq: CELU; CELUW) (“Celularity”), a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, today announced that its Board of Directors has approved a 1-for-10 reverse st...

CELUW - General Electric's CFO Carolina Dybeck Happe Steps Down: C-Suite Transitions

2023-05-26 11:56:25 ET Summary Even with new management in place, it is unlikely that a company will regain market share or turn profitable after it has lost its way. Carolina Dybeck Happe joined General Electric Company in March 2020 at a time when revenue had been declining shar...

CELUW - Celularity: Funds Infusion Needed ASAP To Advance

Celularity posted revenue of $21.3M and diluted EPS of -$1.49 for FY-2021. The Company received five FDA fast track/orphan-drug destinations in FY-2021 for its lead candidates. The stock price is up 38%+ since our last coverage in September 2021, however, the company is in need of...
Previous 10 Next 10